Literature DB >> 28650455

Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.

S Nguyen1,2, A Achour2, L Souchet1, S Vigouroux3, P Chevallier4, S Furst5, A Sirvent6, J-O Bay7, G Socié8, P Ceballos9, A Huynh10, J Cornillon11, S Francois12, F Legrand13, I Yakoub-Agha14, G Michel15, N Maillard16, G Margueritte17, S Maury18, M Uzunov1, C-E Bulabois19, M Michallet20, L Clement21, C Dauriac22, K Bilger23, J Lejeune24, V Béziat2, V Rocha25, B Rio26, S Chevret24, V Vieillard2.   

Abstract

Unrelated cord blood transplantation (UCBT) after a reduced intensity conditioning regimen (RIC) has extended the use of UCB in elderly patients and those with co-morbidities without an HLA-identical donor, although post-transplant relapse remains a concern in high-risk acute myeloid leukemia (AML) patients. HLA incompatibilities between donor and recipient might enhance the alloreactivity of natural killer (NK) cells after allogeneic hematopoietic stem-cell transplantation (HSCT). We studied the reconstitution of NK cells and KIR-L mismatch in 54 patients who underwent a RIC-UCBT for AML in CR in a prospective phase II clinical trial. After RIC-UCBT, NK cells displayed phenotypic features of both activation and immaturity. Restoration of their polyfunctional capacities depended on the timing of their acquisition of phenotypic markers of maturity. The incidence of treatment-related mortality (TRM) was correlated with low CD16 expression (P=0.043) and high HLA-DR expression (P=0.0008), whereas overall survival was associated with increased frequency of NK-cell degranulation (P=0.001). These features reflect a general impairment of the NK licensing process in HLA-mismatched HSCT and may aid the development of future strategies for selecting optimal UCB units and enhancing immune recovery.

Entities:  

Mesh:

Year:  2017        PMID: 28650455     DOI: 10.1038/bmt.2017.122

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  42 in total

1.  Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.

Authors:  M Pfeiffer; S Stanojevic; T Feuchtinger; J Greil; R Handgretinger; K Barbin; G Jung; D Martin; D Niethammer; P Lang
Journal:  Bone Marrow Transplant       Date:  2005-07       Impact factor: 5.483

2.  An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.

Authors:  Nicolas Dulphy; Philippe Haas; Marc Busson; Stéphanie Belhadj; Régis Peffault de Latour; Marie Robin; Maryvonnick Carmagnat; Pascale Loiseau; Ryad Tamouza; Catherine Scieux; Claire Rabian; James P Di Santo; Dominique Charron; Anne Janin; Gérard Socié; Antoine Toubert
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

Review 3.  Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?

Authors:  Stéphanie Nguyen; Vivien Béziat; Damien Roos-Weil; Vincent Vieillard
Journal:  J Innate Immun       Date:  2011-03-12       Impact factor: 7.349

4.  Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases.

Authors:  A Ruggeri; R Peffault de Latour; M Carmagnat; E Clave; C Douay; J Larghero; J-M Cayuela; R Traineau; M Robin; A Madureira; P Ribaud; C Ferry; A Devergie; D Purtill; C Rabian; E Gluckman; A Toubert; G Socié; V Rocha
Journal:  Transpl Infect Dis       Date:  2011-04-05       Impact factor: 2.228

5.  Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Authors:  Bernard Rio; Sylvie Chevret; Stéphane Vigouroux; Patrice Chevallier; Sabine Fürst; Anne Sirvent; Jacques-Olivier Bay; Gérard Socié; Patrice Ceballos; Anne Huynh; Jérôme Cornillon; Sylvie Françoise; Faezeh Legrand; Ibrahim Yakoub-Agha; Gérard Michel; Natacha Maillard; Geneviève Margueritte; Sébastien Maury; Madalina Uzunov; Claude Eric Bulabois; Mauricette Michallet; Laurence Clement; Charles Dauriac; Karin Bilger; Eliane Gluckman; Annalisa Ruggeri; Agnès Buzyn; Stéphanie Nguyen; Tabassome Simon; Nöel Milpied; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-18       Impact factor: 5.742

6.  Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Authors:  Filippo Milano; Ted Gooley; Brent Wood; Ann Woolfrey; Mary E Flowers; Kristine Doney; Robert Witherspoon; Marco Mielcarek; Joachim H Deeg; Mohamed Sorror; Ann Dahlberg; Brenda M Sandmaier; Rachel Salit; Effie Petersdorf; Frederick R Appelbaum; Colleen Delaney
Journal:  N Engl J Med       Date:  2016-09-08       Impact factor: 91.245

7.  Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome.

Authors:  Gérard Michel; Claire Galambrun; Anne Sirvent; Cecile Pochon; Benedicte Bruno; Charlotte Jubert; Anderson Loundou; Ibrahim Yakoub-Agha; Noel Milpied; Patrick Lutz; Aude Marie-Cardine; Virginie Gandemer; Didier Blaise; Mauricette Michallet; Fanny Rialland; Cecile Renard; Claire Oudin; Sophie Esmiol; Mylene Seux; Karine Baumstarck; Mohamad Mohty; Vanderson Rocha; Jean-Hugues Dalle
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

8.  Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.

Authors:  Claudio G Brunstein; John E Wagner; Daniel J Weisdorf; Sarah Cooley; Harriet Noreen; Juliet N Barker; Todd DeFor; Michael R Verneris; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

Review 9.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

10.  Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population.

Authors:  Annettee Nakimuli; Olympe Chazara; Lydia Farrell; Susan E Hiby; Stephen Tukwasibwe; Olatejumoye Knee; Jyothi Jayaraman; James A Traherne; Alison M Elliott; Pontiano Kaleebu; Florence Mirembe; Ashley Moffett
Journal:  Immunogenetics       Date:  2013-08-24       Impact factor: 2.846

View more
  5 in total

1.  Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.

Authors:  Ioannis Politikos; Jessica A Lavery; Patrick Hilden; Christina Cho; Taylor Borrill; Molly A Maloy; Sergio A Giralt; Marcel R M van den Brink; Miguel-Angel Perales; Juliet N Barker
Journal:  Blood Adv       Date:  2020-01-14

2.  Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients.

Authors:  John Girdlestone; Meera Raymond; Bronwen Shaw; Sameer Tulpule; Vikesh R Devlia; Robert Danby; Trudy Ahyee; Aurore Saudemont; Rachael Hough; Paul Veys; Annalisa Ruggeri; Ajay Vora; David I Marks; Brenda Gibson; Robert Wynn; Alejandro Madrigal; Cristina V Navarrete
Journal:  EJHaem       Date:  2020-05-21

3.  HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection.

Authors:  Nadia Wauquier; Caroline Petitdemange; Nadine Tarantino; Christopher Maucourant; Moinya Coomber; Victor Lungay; James Bangura; Patrice Debré; Vincent Vieillard
Journal:  EBioMedicine       Date:  2019-01-30       Impact factor: 8.143

Review 4.  Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation.

Authors:  Hyun Don Yun; Ankur Varma; Mohammad J Hussain; Sunita Nathan; Claudio Brunstein
Journal:  J Clin Med       Date:  2019-11-14       Impact factor: 4.241

Review 5.  CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

Authors:  Mohamad Sabbah; Ludovic Jondreville; Claire Lacan; Francoise Norol; Vincent Vieillard; Damien Roos-Weil; Stéphanie Nguyen
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.